Insider Transactions in Q1 2025 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2025
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19,512
-7.28%
|
$0
$0.6 P/Share
|
|
Mar 18
2025
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
10,203
-7.8%
|
$0
$0.6 P/Share
|
|
Mar 18
2025
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,025
-2.88%
|
$0
$0.6 P/Share
|
|
Mar 18
2025
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,551
-4.08%
|
$0
$0.6 P/Share
|
|
Mar 18
2025
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
37,656
-3.65%
|
$0
$0.6 P/Share
|
|
Feb 04
2025
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,500
+21.98%
|
-
|
|
Feb 04
2025
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
113,500
+34.83%
|
-
|
|
Feb 04
2025
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+15.33%
|
-
|
|
Feb 04
2025
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
375,000
+16.78%
|
-
|